Academic Press Protein-Protein Interactions in Human Disease, Part A (Volume 110) (Advances in Protein Chemistry and Structural Biology, Volume 110)

Product Description Protein-Protein Interactions in Human Disease, Part A, Volume 110 aims to promote further research and development in the protein interaction network as a means to not only identify the critical proteins involved in the etiology of human diseases, but also identify new protein targets for drug development. Sections cover such topics as protein-protein interaction modulators for epigenetic therapies, intrinsic disorder, protein-protein interactions and disease, targeting protein-protein interactions in the ubiquitin-proteasome pathway, the proteomics of occupational diseases, and computational methods in predicting the impact of SNPs in protein-protein network, amongst other topics. Describes advances in the application of powerful techniques in studying and analyzing protein-protein interactions Targeted to a wide audience of researchers, specialists and students Written by authorities in their field Includes information that is well supported by a number of high quality illustrations, figures and tables Review "...all of the authors of the book succeeded in showing highly exciting and unique opportunities for unraveling the functional behavior of complex protein-protein interactions in human diseases. ...The volume shows the enormous complexity in the field of PPI in human diseases. It is a collection of topics without pretending in-depth analysis of a single subject. Each theme and chapter stands on its own, but all have protein-protein interactions in common." --The Quarterly Review of Biology Review Overview of advances in the role of protein-protein interactions in human diseases, with promising new strategies based on targeting protein interactions About the Author Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2010 Dr. Donev was appointed Senior Lecturer in Swansea University. Currently he is Head of Research at MicroPharm Ltd, UK and Director of Biomed Consult, UK. He has published more than 60 research papers, has chaired scientific meetings in Molecular Medicine and given plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on design of antibody-based oral treatment of pathological conditions of the colon and small intestines.